ACADIA Pharmaceuticals Inc
ACAD27.545USD
-0.325-1.17%
Market hours （ET）Quotes delayed by 15 min
4.66BMarket Cap
17.59P/E TTM
More Details of ACADIA Pharmaceuticals Inc Company
Acadia Pharmaceuticals Inc. is a biopharmaceutical company. It develops and commercializes medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has a portfolio of product candidates and research programs that are designed to address significant unmet medical needs in CNS disorders and rare diseases. Its pipeline includes NUPLAZID (pimavanserin), DAYBUE (trofinetide), ACP-101, ACP-204, and ACP-711. NUPLAZID is a selective serotonin inverse agonist/antagonist preferentially targeting the 5-HT2A receptor. NUPLAZID is developed for the treatment for Parkinson's Disease Psychosis. Trofinetide is a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 designed to treat the core symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function. Its early-stage research programs and product candidates include ACP-211, ACP-2591, ACP-271, and Antisense Oligonucleotide (ASO) Programs.
ACADIA Pharmaceuticals Inc Info
Ticker SymbolACAD
Company nameACADIA Pharmaceuticals Inc
IPO dateMay 27, 2004
CEOOwen Adams (Catherine Owen)
Number of employees653
Security typeOrdinary Share
Fiscal year-endMay 27
Address12830 El Camino Real
CitySAN DIEGO
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code92130
Phone18585582871
Websitehttps://acadia.com/
Ticker SymbolACAD
IPO dateMay 27, 2004
CEOOwen Adams (Catherine Owen)
Company Executives of ACADIA Pharmaceuticals Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Julian C. Baker
Mr. Julian C. Baker
Independent Director
Independent Director
102.88K
--
Dr. Adora Ndu, Pharm.D.
Dr. Adora Ndu, Pharm.D.
Independent Director
Independent Director
24.80K
+60.90%
Ms. Laura A. Brege
Ms. Laura A. Brege
Independent Director
Independent Director
15.10K
-48.90%
Mr. James Michael (Jim) Daly
Mr. James Michael (Jim) Daly
Independent Director
Independent Director
--
--
Dr. Stephen R. Biggar, M.D., Ph.D.
Dr. Stephen R. Biggar, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Elizabeth H. Z. Thompson, Ph.D.
Dr. Elizabeth H. Z. Thompson, Ph.D.
Executive Vice President and Head of Research and Development
Executive Vice President and Head of Research and Development
--
--
Mr. Mark C. Schneyer
Mr. Mark C. Schneyer
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
--
--
Dr. Edmund P. Harrigan
Dr. Edmund P. Harrigan
Independent Director
Independent Director
--
--
Mr. Thomas Andrew (Tom) Garner
Mr. Thomas Andrew (Tom) Garner
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
--
--
Ms. Catherine Owen Adams
Ms. Catherine Owen Adams
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Julian C. Baker
Mr. Julian C. Baker
Independent Director
Independent Director
102.88K
--
Dr. Adora Ndu, Pharm.D.
Dr. Adora Ndu, Pharm.D.
Independent Director
Independent Director
24.80K
+60.90%
Ms. Laura A. Brege
Ms. Laura A. Brege
Independent Director
Independent Director
15.10K
-48.90%
Mr. James Michael (Jim) Daly
Mr. James Michael (Jim) Daly
Independent Director
Independent Director
--
--
Dr. Stephen R. Biggar, M.D., Ph.D.
Dr. Stephen R. Biggar, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Elizabeth H. Z. Thompson, Ph.D.
Dr. Elizabeth H. Z. Thompson, Ph.D.
Executive Vice President and Head of Research and Development
Executive Vice President and Head of Research and Development
--
--
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023Q2
FY2023Q1
By BusinessUSD
Name
Revenue
Proportion
NUPLAZID
168.48M
63.68%
DAYBUE
96.09M
36.32%
Relevant data have not been disclosed by the company yet.
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
NUPLAZID
168.48M
63.68%
DAYBUE
96.09M
36.32%
Shareholding Stats
Updated: Wed, Nov 19
Updated: Wed, Nov 19
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Baker Bros. Advisors LP
25.36%
BlackRock Institutional Trust Company, N.A.
10.61%
The Vanguard Group, Inc.
8.96%
State Street Investment Management (US)
4.29%
RTW Investments L.P.
4.22%
Other
46.57%
Shareholders
Shareholders
Proportion
Baker Bros. Advisors LP
25.36%
BlackRock Institutional Trust Company, N.A.
10.61%
The Vanguard Group, Inc.
8.96%
State Street Investment Management (US)
4.29%
RTW Investments L.P.
4.22%
Other
46.57%
Shareholder Types
Shareholders
Proportion
Hedge Fund
36.24%
Investment Advisor
34.15%
Investment Advisor/Hedge Fund
25.99%
Research Firm
2.78%
Pension Fund
1.04%
Sovereign Wealth Fund
0.91%
Individual Investor
0.55%
Private Equity
0.36%
Bank and Trust
0.35%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
678
172.21M
111.07%
+88.91K
2025Q3
694
172.14M
111.53%
-1.01M
2025Q2
679
173.11M
115.05%
-3.45M
2025Q1
670
176.73M
110.29%
-7.23M
2024Q4
628
165.93M
106.75%
+6.22M
2024Q3
584
159.68M
110.26%
-6.09M
2024Q2
587
164.94M
112.25%
-1.65M
2024Q1
596
166.68M
110.85%
-15.97M
2023Q4
576
164.23M
109.91%
+3.11M
2023Q3
548
160.78M
109.90%
-3.01M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Baker Bros. Advisors LP
42.90M
25.43%
+18.77K
+0.04%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
18.22M
10.8%
-552.34K
-2.94%
Jun 30, 2025
The Vanguard Group, Inc.
15.24M
9.03%
+61.01K
+0.40%
Jun 30, 2025
State Street Investment Management (US)
6.18M
3.66%
-815.47K
-11.66%
Jun 30, 2025
RTW Investments L.P.
9.00M
5.33%
+455.43K
+5.33%
Jun 30, 2025
Geode Capital Management, L.L.C.
3.02M
1.79%
+69.58K
+2.36%
Jun 30, 2025
Dimensional Fund Advisors, L.P.
2.40M
1.42%
+740.23K
+44.72%
Jun 30, 2025
Palo Alto Investors LP
2.56M
1.52%
-100.72K
-3.78%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Alger Weatherbie Enduring Growth ETF
4.1%
First Trust NYSE Arca Biotechnology Index Fund
3.8%
iShares Neuroscience and Healthcare ETF
3.48%
Invesco Biotechnology & Genome ETF
2.34%
Invesco S&P SmallCap Health Care ETF
1.73%
Virtus LifeSci Biotech Products ETF
1.67%
ALPS Medical Breakthroughs ETF
1.58%
Invesco S&P SmallCap 600 GARP ETF
1.23%
State Street SPDR S&P Biotech ETF
1.08%
Lattice Hartford Multifactor Small Cap ETF
0.72%
View more
Alger Weatherbie Enduring Growth ETF
Proportion4.1%
First Trust NYSE Arca Biotechnology Index Fund
Proportion3.8%
iShares Neuroscience and Healthcare ETF
Proportion3.48%
Invesco Biotechnology & Genome ETF
Proportion2.34%
Invesco S&P SmallCap Health Care ETF
Proportion1.73%
Virtus LifeSci Biotech Products ETF
Proportion1.67%
ALPS Medical Breakthroughs ETF
Proportion1.58%
Invesco S&P SmallCap 600 GARP ETF
Proportion1.23%
State Street SPDR S&P Biotech ETF
Proportion1.08%
Lattice Hartford Multifactor Small Cap ETF
Proportion0.72%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of ACADIA Pharmaceuticals Inc?
The top five shareholders of ACADIA Pharmaceuticals Inc are:
Baker Bros. Advisors LP holds 42.90M shares, accounting for 25.43% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 18.22M shares, accounting for 10.80% of the total shares.
The Vanguard Group, Inc. holds 15.24M shares, accounting for 9.03% of the total shares.
State Street Investment Management (US) holds 6.18M shares, accounting for 3.66% of the total shares.
RTW Investments L.P. holds 9.00M shares, accounting for 5.33% of the total shares.
Baker Bros. Advisors LP holds 42.90M shares, accounting for 25.43% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 18.22M shares, accounting for 10.80% of the total shares.
The Vanguard Group, Inc. holds 15.24M shares, accounting for 9.03% of the total shares.
State Street Investment Management (US) holds 6.18M shares, accounting for 3.66% of the total shares.
RTW Investments L.P. holds 9.00M shares, accounting for 5.33% of the total shares.
What are the top three shareholder types of ACADIA Pharmaceuticals Inc?
The top three shareholder types of ACADIA Pharmaceuticals Inc are:
Baker Bros. Advisors LP
BlackRock Institutional Trust Company, N.A.
The Vanguard Group, Inc.
Baker Bros. Advisors LP
BlackRock Institutional Trust Company, N.A.
The Vanguard Group, Inc.
How many institutions hold shares of ACADIA Pharmaceuticals Inc (ACAD)?
As of 2025Q4, 678 institutions hold shares of ACADIA Pharmaceuticals Inc, with a combined market value of approximately 172.21M, accounting for 111.07% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -0.47%.
What is the biggest source of revenue for ACADIA Pharmaceuticals Inc?
In FY2025Q2, the NUPLAZID business generated the highest revenue for ACADIA Pharmaceuticals Inc, amounting to 168.48M and accounting for 63.68% of total revenue.
